Loading clinical trials...
Loading clinical trials...
The Role of Alpha Melanocyte Stimulating Hormone in Ocular Disease
The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease. Alpha MSH has been shown to have an important role in the regulation of ocular immunity in animal models of inflammatory retinal diseases and retinal dystrophies, and there may be a protective effect of alpha MSH. By studying the levels of alpha MSH in your eye we may better understand its role in advanced dry macular degeneration. By studying the levels of this molecule we hope to better understand if it may be a good target for future treatment.
A small amount (0.1 mL) of aqueous humor would be removed from the study eye in the clinic setting. This sample will be processed and then sent off for measurement of alpha MSH levels.
Age
60 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Duke University Eye Center
Durham, North Carolina, United States
Start Date
March 6, 2018
Primary Completion Date
October 19, 2021
Completion Date
October 19, 2021
Last Updated
December 22, 2022
54
ACTUAL participants
Alpha MSH assay
DEVICE
Lead Sponsor
Duke University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions